CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 77 enrolled
Drug / intervention
sunitinib +1 moredrug
Likely dose
sunitinib 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01934452
NCT01934452N/ACompleted
CompareCT.gov

Prospective Study of Complete Remissions Observed With Sunitinib in Patients With Metastatic Renal Cell Carcinoma mRCC)

Pfizer·observational·Posted Sep 4, 2013·Updated Nov 13, 2023

In Brief

An observational study evaluating sunitinib for Complete Remission in Renal Cell Carcinoma. Completed, enrolled 77 participants across 14 sites.

Detailed Summary

This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib, in order to provide some answers/ refection leads to the following questions : Can we identify blood specificity at time of CR vs non on CR? Shall we distinguish CR with sunitinib alone from combined CR (sunitinib with local treatment), while in clinical report these 2 cohorts present similar time to recurrence (ALBIGES, ASCO 2010)? Can we identify potential predictive serum biomarkers of recurrence? (With the aim of isolating blood biomarker that can help on treatment discontinuation decision?)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsComplete Remission in Renal Cell Carcinoma
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 4, 2013
Enrollment StartMay 21, 2015
Primary CompletionJan 19, 2022
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 12.8 years ago

Interventions

sunitinibdrug

50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months

sunitinibdrug

50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months